Qiagen snares key assets of two biotech companies

Dutch biotech Qiagen is buying up the key assets of two biotech firms for up to $18 million. The bulk of that goes to buy the assets of LumiCyte in Fremont, California. LumiCyte makes protein analysis tools. Qiagen is also buying the bioanalytical assets of SuNyx, a German biotech that markets bioanalytic solutions to the biopharma industry.

- read this press release and this press release for more on both

Suggested Articles

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.

The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year. 

Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process.